Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study

Utility of Glucose Transporter 1 in the Distinction of Benign and Malignant Thoracic and Abdominal Mesothelial Lesions

(2012) Stephen M. Lagana et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma

(2012) Kyoichi Kaira et al.   EUROPEAN JOURNAL OF CANCER

The Diagnostic Utility ofp16FISH and GLUT-1 Immunohistochemical Analysis in Mesothelial Proliferations

(2011) Sara E. Monaco et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin

(2010) Aaron U. Blackham et al.   ANNALS OF SURGICAL ONCOLOGY

A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*

(2010) Tristan D. Yan et al.   CANCER

Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials

(2010) M.D. Kluger et al.   EJSO

CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival

(2010) Alyssa M Krasinskas et al.   MODERN PATHOLOGY

Glucose Transporter-1 (GLUT-1) Immunoreactivity in Benign, Premalignant and Malignant Lesions of the Gallbladder

(2010) Mateja Legan et al.   PATHOLOGY & ONCOLOGY RESEARCH

Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for the Treatment of Malignant Peritoneal Mesothelioma

(2009) Mary E. Hesdorffer et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma

(2009) Dario Baratti et al.   ANNALS OF SURGICAL ONCOLOGY

Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma

(2009) Wiebke Fenske et al.   ENDOCRINE-RELATED CANCER

Mésothéliome péritonéal : traitement par l’association chirurgie de cytoréduction et chimiothérapie hyperthermique intrapéritonéale

(2009) G. Passot et al.   JOURNAL DE CHIRURGIE

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience

(2009) Tristan D. Yan et al.   JOURNAL OF CLINICAL ONCOLOGY

Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis

(2009) Irem H Ozbudak et al.   MODERN PATHOLOGY

Impact of Tumor Angiogenesis in Peritoneal Mesothelioma After Radical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy

(2009) Terence C. Chua et al.   PATHOLOGY & ONCOLOGY RESEARCH

Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract

(2009) Ji-Youn Sung et al.   PATHOLOGY RESEARCH AND PRACTICE

Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

(2008) D. Baratti et al.   ANNALS OF SURGICAL ONCOLOGY

Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience

(2008) Terence C. Chua et al.   JOURNAL OF SURGICAL ONCOLOGY

Pulmonary

(2008)   MODERN PATHOLOGY